Download the app
App StorePlay Store
Beige
Login
← All tags

semaglutide

Dr Reddy’s launches generic Semaglutide in Canada first G7 approval could widen GLP-1 access fast

Dr Reddy’s launches generic Semaglutide in Canada first G7 approval could widen GLP-1 access fast

Dr Reddy’s Laboratories has launched a generic Semaglutide injection in Canada for adults with type 2 diabetes, following Health Canada approval granted on April 28, 2026. The move makes Canada the first G7 nation to authorize Semaglutide, positioning the company among the earliest generics entrants in that market. The launch follows Dr Reddy’s recent introduction in India under the brand name Obeda. Supplied as a sterile prefilled pen, it is offered in 2 mg and 4 mg strengths.

Summarised by Beize from a story on The Economic Times on 16 May 2026
Dr Reddy’s bets on semaglutide and abatacept to revive margins and momentum by FY27

Dr Reddy’s bets on semaglutide and abatacept to revive margins and momentum by FY27

Dr Reddy’s Laboratories expects a gradual recovery in the coming fiscal year after last year’s profit dip hit by pressures in the US business. Growth remains solid across India, Europe, and emerging markets. The company’s outlook leans on upcoming launches including semaglutide and abatacept, alongside improved product mix and tighter cost controls to lift margins by FY27.

Summarised by Beize from a story on The Economic Times on 14 May 2026

Your news, in seconds

App StorePlay Store
Generic semaglutide prices in India may crash by half with new brands and lower raw costs

Generic semaglutide prices in India may crash by half with new brands and lower raw costs

Generic semaglutide in India is expected to get dramatically cheaper, with prices likely to fall by more than half in the coming months. The drop is linked to the entry of smaller brands and a steep decline in raw material costs. A one month dose could fall to as low as ₹500, potentially widening access to the popular weight-loss drug.

Summarised by Beize from a story on The Economic Times on 13 May 2026
Kiran Mazumdar Shaw hands Biocon reins to niece Claire and targets semaglutide push from FY28

Kiran Mazumdar Shaw hands Biocon reins to niece Claire and targets semaglutide push from FY28

Biocon’s Executive Chairperson Kiran Mazumdar-Shaw has mapped a five-year succession plan, naming her niece Claire Mazumdar as successor. The company expects a strong FY27 launch calendar, especially in the second half, driven by its “diabesity” franchise. It also reports significant debt reduction and will channel more operational cash flow toward further deleveraging as it targets a semaglutide push from FY28.

Summarised by Beize from a story on The Economic Times on 11 May 2026
Torrent wins 38 percent share as semaglutide generics surge across India

Torrent wins 38 percent share as semaglutide generics surge across India

After Novo Nordisk’s innovator semaglutide patent expired in end-March, over a dozen Indian firms launched generics. In April, these generics sold about ₹44 crore in total, with Torrent emerging as the fastest mover, grabbing around 38% market share. The sprint signals intensifying competition in GLP-1 diabetes and weight-management drugs.

Summarised by Beize from a story on The Economic Times on 7 May 2026
GLP 1 weight loss drugs may reduce alcohol binges by half in new trial

GLP 1 weight loss drugs may reduce alcohol binges by half in new trial

A new trial suggests GLP-1 weight-loss drugs such as semaglutide could also curb heavy alcohol use. Researchers report weekly injections halved heavy drinking days among adults with alcohol use disorder. Because the same medicine is already used for obesity, the findings could translate into a new treatment pathway for millions, pending further research.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026

Never miss a story

App StorePlay Store
Dr Reddy’s wins Health Canada approval for generic semaglutide injection first in Canada

Dr Reddy’s wins Health Canada approval for generic semaglutide injection first in Canada

Dr Reddy’s Laboratories has received market authorization from Health Canada for its generic semaglutide injection, becoming the first company approved for the diabetes therapy in Canada. The Bengaluru-based pharma is now preparing a launch to expand access for patients who rely on the treatment, potentially easing pressure on medication availability and costs.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026
Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets

Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets

Semaglutide API prices are falling sharply as global demand for weight-loss drugs like Ozempic and Wegovy drives rapid manufacturing expansion. With patents set to expire in key markets and Indian companies rolling out lower-priced generics, analysts expect additional price softening. The shift could widen access to these GLP-1 therapies for patients in the months ahead.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Generic semaglutide rush hits India as Novo Nordisk patent fallout reshapes obesity drug prices

Generic semaglutide rush hits India as Novo Nordisk patent fallout reshapes obesity drug prices

India’s weight-loss drug market is rapidly shifting as generic semaglutide becomes available after Novo Nordisk’s patent loss. The cheaper alternatives are already pressuring Eli Lilly’s sales while unlocking a surge in demand. With multiple Indian drugmakers racing to launch affordable options, the country’s obesity-treatment landscape is entering a new, more price-accessible phase.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Mounjaro sales dip in India as Ozempic price cuts and semaglutide generics surge

Mounjaro sales dip in India as Ozempic price cuts and semaglutide generics surge

Mounjaro sales are sliding across India as Novo Nordisk drives a price war for Ozempic and Wegovy and cheaper semaglutide generics gain traction. Eli Lilly says it’s seeing increased competition but remains confident in Mounjaro’s differentiated benefits for users. The shift highlights how rapidly GLP-1 therapy markets are being reshaped by pricing pressure.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Reading on mobile?

App StorePlay Store
Dr Reddy’s wins approval for generic oral semaglutide after head to head trial

Dr Reddy’s wins approval for generic oral semaglutide after head to head trial

Dr Reddy’s has received regulatory approval in India to roll out its generic oral semaglutide. The approval follows a head to head comparative study in India that found the formulation non inferior to Novo Nordisk’s Rybelsus. The company says this clinical evidence helped it secure approval under India’s biosimilar regulatory pathway.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play